Surgery Partners Inc. (SGRY) stock surged 5.08% on Tuesday, as analysts view the recent selloff in the shares as an overreaction to the company's latest earnings report.
Following Surgery Partners' earnings release, the stock suffered a sharp decline, plunging 31% over the past five trading sessions. However, analysts at Macquarie believe this selloff is overdone and see an undervalued opportunity in the stock.
In a research note, Macquarie analyst Tao Qiu maintained a "Buy" rating on SGRY, citing the company's strong fundamentals. Qiu's bullish stance is based on the belief that Surgery Partners' business model remains intact and that the company is well-positioned to capitalize on the growing demand for surgical services.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。